Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C10H6O4.C4H11N |
| Molecular Weight | 263.2891 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCNCC.OC(=O)C1=CC(=O)C2=C(O1)C=CC=C2
InChI
InChIKey=BTDWBTIPKMIUHM-UHFFFAOYSA-N
InChI=1S/C10H6O4.C4H11N/c11-7-5-9(10(12)13)14-8-4-2-1-3-6(7)8;1-3-5-4-2/h1-5H,(H,12,13);5H,3-4H2,1-2H3
| Molecular Formula | C4H11N |
| Molecular Weight | 73.1368 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C10H6O4 |
| Molecular Weight | 190.1522 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Chromocarb is benzo-γ-pyrone derivative with vasoprotection activity used to eliminate lipoperoxidation post-vitrectomy. Peroral treatment of rats with chromocarb significantly reduced the degradation of the vascular wall by intravenous collagenase, as demonstrated by a lesser permeability increase of the blood-brain barrier, a shorter recovery time, lower hydroxyproline levels in the cerebrospinal fluid and a lesser decrease of the collagen content of the brain capillary basal lamina.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: GO:0006629 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11881979 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11881979
rats: 50 mg/kg daily in drinking water for 30 days
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:52:41 GMT 2025
by
admin
on
Mon Mar 31 18:52:41 GMT 2025
|
| Record UNII |
R0O8TF63DH
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
48064
Created by
admin on Mon Mar 31 18:52:41 GMT 2025 , Edited by admin on Mon Mar 31 18:52:41 GMT 2025
|
PRIMARY | RxNorm | ||
|
DTXSID10178628
Created by
admin on Mon Mar 31 18:52:41 GMT 2025 , Edited by admin on Mon Mar 31 18:52:41 GMT 2025
|
PRIMARY | |||
|
R0O8TF63DH
Created by
admin on Mon Mar 31 18:52:41 GMT 2025 , Edited by admin on Mon Mar 31 18:52:41 GMT 2025
|
PRIMARY | |||
|
159960
Created by
admin on Mon Mar 31 18:52:41 GMT 2025 , Edited by admin on Mon Mar 31 18:52:41 GMT 2025
|
PRIMARY | |||
|
m3511
Created by
admin on Mon Mar 31 18:52:41 GMT 2025 , Edited by admin on Mon Mar 31 18:52:41 GMT 2025
|
PRIMARY | Merck Index | ||
|
SUB01284MIG
Created by
admin on Mon Mar 31 18:52:41 GMT 2025 , Edited by admin on Mon Mar 31 18:52:41 GMT 2025
|
PRIMARY | |||
|
23915-80-2
Created by
admin on Mon Mar 31 18:52:41 GMT 2025 , Edited by admin on Mon Mar 31 18:52:41 GMT 2025
|
PRIMARY | |||
|
100000084807
Created by
admin on Mon Mar 31 18:52:41 GMT 2025 , Edited by admin on Mon Mar 31 18:52:41 GMT 2025
|
PRIMARY | |||
|
245-939-9
Created by
admin on Mon Mar 31 18:52:41 GMT 2025 , Edited by admin on Mon Mar 31 18:52:41 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |